Direct comparison finds Eliquis safer from bleeding than Xarelto in venous clots
A NEJM trial comparing apixaban (Eliquis) and rivaroxaban (Xarelto) found Eliquis had a lower risk of clinically relevant bleeding in patients with venous thromboembolism, with similar efficacy in preventing recurrent clots; however, results may not generalize beyond a largely white, healthy population, suggesting Eliquis could be a safer first-line option for many patients.
